<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35034660</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Short structural variants as informative genetic markers for ALS disease risk and progression.</ArticleTitle><Pagination><StartPage>11</StartPage><MedlinePgn>11</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-021-02206-y</ELocationID><Abstract><AbstractText>There is considerable variability in disease progression for patients with amyotrophic lateral sclerosis (ALS) including the age of disease onset, site of disease onset, and survival time. There is growing evidence that short structural variations (SSVs) residing in frequently overlooked genomic regions can contribute to complex disease mechanisms and can explain, in part, the phenotypic variability in ALS patients. Here, we discuss SSVs recently characterized by our laboratory and how these discoveries integrate into the current literature on ALS, particularly in the context of application to future clinical trials. These markers may help to identify and differentiate patients for clinical trials that have a similar ALS disease mechanism(s), thereby reducing the impact of participant heterogeneity. As evidence accumulates for the genetic markers discovered in SQSTM1, SCAF4, and STMN2, we hope to improve the outcomes of future ALS clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Theunissen</LastName><ForeName>Frances</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7092-8344</Identifier><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, First floor, RR block, QEII Medical Centre, 8 Verdun St, Nedlands, WA, 6009, Australia. Frances.theunissen@perron.uwa.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia. Frances.theunissen@perron.uwa.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flynn</LastName><ForeName>Loren L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, First floor, RR block, QEII Medical Centre, 8 Verdun St, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Swan Pharmaceuticals, Wake Forrest, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderton</LastName><ForeName>Ryan S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Nursing, Midwifery and Health Sciences, University of Notre Dame Australia, Fremantle, WA, 6160, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akkari</LastName><ForeName>P Anthony</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, First floor, RR block, QEII Medical Centre, 8 Verdun St, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Swan Pharmaceuticals, Wake Forrest, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Duke University Medical Centre, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000595774">SCAF4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>170974-22-8</RegistryNumber><NameOfSubstance UI="D000068103">Serine-Arginine Splicing Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068103" MajorTopicYN="N">Serine-Arginine Splicing Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Enrichment tool</Keyword><Keyword MajorTopicYN="N">Genetic marker</Keyword><Keyword MajorTopicYN="N">Participant selection</Keyword><Keyword MajorTopicYN="N">Responder sub-population</Keyword><Keyword MajorTopicYN="N">Structural variant</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>17</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35034660</ArticleId><ArticleId IdType="pmc">PMC8762977</ArticleId><ArticleId IdType="doi">10.1186/s12916-021-02206-y</ArticleId><ArticleId IdType="pii">10.1186/s12916-021-02206-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia AM, Gallo A, Manzari C, Raho S, Horner DS, Chiara M, Valletti A, Aiello I, Mastropasqua F, Ciaccia L, Locatelli F, Pisani F, Nicchia GP, Svelto M, Pesole G, Picardi E. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci Rep. 2017;7(1):10046. doi: 10.1038/s41598-017-10488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10488-7</ArticleId><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Krokidis MG, Vlamos P. Transcriptomics in amyotrophic lateral sclerosis. Front Biosci (Elite Ed) 2018;10:103&#x2013;121. doi: 10.2741/e811.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/e811</ArticleId><ArticleId IdType="pubmed">28930607</ArticleId></ArticleIdList></Reference><Reference><Citation>Recabarren-Leiva D, Alarc&#xf3;n M. New insights into the gene expression associated to amyotrophic lateral sclerosis. Life Sci. 2018;193:110&#x2013;123. doi: 10.1016/j.lfs.2017.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2017.12.016</ArticleId><ArticleId IdType="pubmed">29241710</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler and Frontotemporal Degener. 2020;21(7-8):1&#x2013;6. doi: 10.1080/21678421.2020.1788092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1788092</ArticleId><ArticleId IdType="pubmed">32643415</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RP, Eijkemans MJ, Nikolakopoulos S, Jansen MD, Westeneng H-J, Van Eijk KR, et al. Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure? Pharmacogenomics J. 2019:1&#x2013;7.</Citation></Reference><Reference><Citation>Van Eijk RP, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurol. 2017;89(18):1915&#x2013;1922. doi: 10.1212/WNL.0000000000004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses A. Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision Clin Pharmacol Ther. 2016;99(2):169&#x2013;171. doi: 10.1002/cpt.288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.288</ArticleId><ArticleId IdType="pmc">PMC4737274</ArticleId><ArticleId IdType="pubmed">26517180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron DL, Di Stefano L, Papenfuss AT. Comprehensive evaluation and characterisation of short read general-purpose structural variant calling software. Nat Commun. 2019;10(1):3240. doi: 10.1038/s41467-019-11146-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11146-4</ArticleId><ArticleId IdType="pmc">PMC6642177</ArticleId><ArticleId IdType="pubmed">31324872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbert MTW, Jensen TD, Jansen-West K, Sens JP, Reddy JS, Ridge PG, Kauwe JSK, Belzil V, Pregent L, Carrasquillo MM, Keene D, Larson E, Crane P, Asmann YW, Ertekin-Taner N, Younkin SG, Ross OA, Rademakers R, Petrucelli L, Fryer JD. Systematic analysis of dark and camouflaged genes reveals disease-relevant genes hiding in plain sight. Genome Biol. 2019;20(1):97. doi: 10.1186/s13059-019-1707-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1707-2</ArticleId><ArticleId IdType="pmc">PMC6526621</ArticleId><ArticleId IdType="pubmed">31104630</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad DF, Hurles ME. The population genetics of structural variation. Nat Genet. 2007;39(7):S30&#x2013;SS6. doi: 10.1038/ng2042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng2042</ArticleId><ArticleId IdType="pmc">PMC2716079</ArticleId><ArticleId IdType="pubmed">17597779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud M, Gobet N, Cruz-D&#xe1;valos DI, Mounier N, Dessimoz C, Sedlazeck FJ. Structural variant calling: the long and the short of it. Genome Biol. 2019;20(1):246. doi: 10.1186/s13059-019-1828-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1828-7</ArticleId><ArticleId IdType="pmc">PMC6868818</ArticleId><ArticleId IdType="pubmed">31747936</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet. 2009;10(4):241&#x2013;251. doi: 10.1038/nrg2554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2554</ArticleId><ArticleId IdType="pubmed">19293820</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68&#x2013;74. doi: 10.1038/nature15393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15393</ArticleId><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Flynn LL, Anderton RS, Mastaglia F, Pytte J, Jiang L, et al. Structural variants may be a source of missing heritability in sALS. Front Neurosci. 2020;14:47. doi: 10.3389/fnins.2020.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00047</ArticleId><ArticleId IdType="pmc">PMC7005198</ArticleId><ArticleId IdType="pubmed">32082115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C, Scott AJ, Davis JR, Tsang EK, Li X, Kim Y, et al. The impact of structural variation on human gene expression. Nat Genet. 2017;49(5):692&#x2013;699. doi: 10.1038/ng.3834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3834</ArticleId><ArticleId IdType="pmc">PMC5406250</ArticleId><ArticleId IdType="pubmed">28369037</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J, Borg A, Fratta P, Orrell RW, Malaspina A, Rowe J, Brown J, Hodges J, Sidle K, Polke JM, Houlden H, Schott JM, Fox NC, Rossor MN, Tabrizi SJ, Isaacs AM, Hardy J, Warren JD, Collinge J, Mead S. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013;92(3):345&#x2013;353. doi: 10.1016/j.ajhg.2013.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakeberg MC, Hoes ME, Gorecki AM, Theunissen F, Pfaff AL, Kenna JE, Plunkett K, K&#xf5;ks S, Akkari PA, Mastaglia FL, Anderton RS. The TOMM40 &#x2018;523&#x2019;polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson&#x2019;s disease. Sci Rep. 2021;11(1):6363. doi: 10.1038/s41598-021-85510-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85510-0</ArticleId><ArticleId IdType="pmc">PMC7973542</ArticleId><ArticleId IdType="pubmed">33737565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakeberg MC, Gorecki AM, Pfaff AL, Hoes ME, K&#xf5;ks S, Akkari PA, Mastaglia FL, Anderton RS. TOMM40 &#x2018;523&#x2019; poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson&#x2019;s disease. NPJ Parkinson&#x2019;s Dis. 2021;7(1):56. doi: 10.1038/s41531-021-00200-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-021-00200-y</ArticleId><ArticleId IdType="pmc">PMC8263775</ArticleId><ArticleId IdType="pubmed">34234128</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses A, Lutz M, Amrine-Madsen H, Saunders A, Crenshaw D, Sundseth S, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer&#x2019;s disease. Pharmacogenomics J. 2010;10(5):375&#x2013;384. doi: 10.1038/tpj.2009.69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tpj.2009.69</ArticleId><ArticleId IdType="pmc">PMC2946560</ArticleId><ArticleId IdType="pubmed">20029386</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Al-Chalabi A. The genetic architecture of ALS. Neurobiol Dis. 2021;147:105156. doi: 10.1016/j.nbd.2020.105156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105156</ArticleId><ArticleId IdType="pubmed">33130222</ArticleId></ArticleIdList></Reference><Reference><Citation>Saul R, Lutz MW, Burns DK, Roses AD, Chiba-Falek O. The SSV evaluation system: a tool to prioritize short structural variants for studies of possible regulatory and causal variants. Hum Mutat. 2016;37(9):877&#x2013;883. doi: 10.1002/humu.23023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23023</ArticleId><ArticleId IdType="pmc">PMC4983215</ArticleId><ArticleId IdType="pubmed">27279261</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W, Van der Spek RAA, Bakker MK, JJFAv V, Hop PJ, RAJ Z, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet.&#xa0;2021;53(12):1636&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48(9):1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyamin B, He J, Zhao Q, Gratten J, Garton F, Leo PJ, Liu Z, Mangelsdorf M, al-Chalabi A, Anderson L, Butler TJ, Chen L, Chen XD, Cremin K, Deng HW, Devine M, Edson J, Fifita JA, Furlong S, Han YY, Harris J, Henders AK, Jeffree RL, Jin ZB, Li Z, Li T, Li M, Lin Y, Liu X, Marshall M, McCann EP, Mowry BJ, Ngo ST, Pamphlett R, Ran S, Reutens DC, Rowe DB, Sachdev P, Shah S, Song S, Tan LJ, Tang L, van den Berg LH, van Rheenen W, Veldink JH, Wallace RH, Wheeler L, Williams KL, Wu J, Wu X, Yang J, Yue W, Zhang ZH, Zhang D, Noakes PG, Blair IP, Henderson RD, McCombe PA, Visscher PM, Xu H, Bartlett PF, Brown MA, Wray NR, Fan D. Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. Nat Commun. 2017;8(1):611. doi: 10.1038/s41467-017-00471-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00471-1</ArticleId><ArticleId IdType="pmc">PMC5606989</ArticleId><ArticleId IdType="pubmed">28931804</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97(6):1268&#x2013;83. e6. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Khleifat A, Iacoangeli A, JJfa VV, Bowles H, RAJ Z, Moisse M, et al. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. NPJ Genom Med. 2021. https://kclpure.kcl.ac.uk/portal/en/publications/structural-variation-analysis-of-6500-whole-genome-sequences-inamyotrophic-lateral-sclerosis(c59ada0f-35ff-4d57-a26c-16ac3e6720f4).html.</Citation></Reference><Reference><Citation>Roses AD, Akkari PA, Chiba-Falek O, Lutz MW, Gottschalk WK, Saunders AM, Saul B, Sundseth S, Burns D. Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing. Expert Opin Drug Metab Toxicol. 2016;12(2):135&#x2013;147. doi: 10.1517/17425255.2016.1133586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425255.2016.1133586</ArticleId><ArticleId IdType="pubmed">26727306</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small G, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Raybould R, Sims R. Searching the dark genome for Alzheimer&#x2019;s disease risk variants. Brain Sci. 2021;11(3):332. doi: 10.3390/brainsci11030332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11030332</ArticleId><ArticleId IdType="pmc">PMC7999247</ArticleId><ArticleId IdType="pubmed">33800766</ArticleId></ArticleIdList></Reference><Reference><Citation>Crenshaw DG, Gottschalk WK, Lutz MW, Grossman I, Saunders AM, Burke JR, Welsh-Bohmer KA, Brannan SK, Burns DK, Roses AD. Using genetics to enable studies on the prevention of Alzheimer&#x2019;s disease. Clin Pharmacol Ther. 2013;93(2):177&#x2013;185. doi: 10.1038/clpt.2012.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.222</ArticleId><ArticleId IdType="pmc">PMC4131283</ArticleId><ArticleId IdType="pubmed">23249780</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns DK, Chiang C, Welsh-Bohmer KA, Brannan SK, Culp M, O'Neil J, Runyan G, Harrigan P, Plassman BL, Lutz M, Lai E, Haneline S, Yarnall D, Yarbrough D, Metz C, Ponduru S, Sundseth S, Saunders AM, TOMMORROW Study Investigators The TOMMORROW study: design of an Alzheimer&#x2019;s disease delay-of-onset clinical trial. Alzheimer&#x2019;s Dement: Transl Res Clin Interv. 2019;5(1):661&#x2013;670. doi: 10.1016/j.trci.2019.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.09.010</ArticleId><ArticleId IdType="pmc">PMC6838537</ArticleId><ArticleId IdType="pubmed">31720367</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11):1108&#x2013;1113. doi: 10.1016/S1474-4422(14)70219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Pytte J, Anderton RS, Flynn LL, Theunissen F, Jiang L, Pitout I, et al. Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis. Neurol Genet. 2020;6:e406. 10.1212/NXG.0000000000000406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7061286</ArticleId><ArticleId IdType="pubmed">32185242</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotsing SF, Margoliash J, Wang C, Saini S, Yanicky R, Shleizer-Burko S, Goren A, Gymrek M. The impact of short tandem repeat variation on gene expression. Nat Genet. 2019;51(11):1652&#x2013;1659. doi: 10.1038/s41588-019-0521-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0521-9</ArticleId><ArticleId IdType="pmc">PMC6917484</ArticleId><ArticleId IdType="pubmed">31676866</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 Mutations in familial and sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2011;68(11):1440&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Rea SL, Majcher V, Searle MS, Layfield R. SQSTM1 mutations&#x2013;bridging Paget disease of bone and ALS/FTLD. Exp Cell Res. 2014;325(1):27&#x2013;37. doi: 10.1016/j.yexcr.2014.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2014.01.020</ArticleId><ArticleId IdType="pubmed">24486447</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Andersen PM, Chioza B, Shaw C, Sham PC, Robberecht W, et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet. 1998;7(13):2045&#x2013;2050. doi: 10.1093/hmg/7.13.2045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/7.13.2045</ArticleId><ArticleId IdType="pubmed">9817920</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed M, Yang Y, Deng HX, Hung WY, Siddique N, Dellefave L, Gellera C, Andersen PM, Siddique T. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72(19):1634&#x2013;1639. doi: 10.1212/01.wnl.0000343509.76828.2a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000343509.76828.2a</ArticleId><ArticleId IdType="pmc">PMC2683645</ArticleId><ArticleId IdType="pubmed">19176896</ArticleId></ArticleIdList></Reference><Reference><Citation>Pytte J, Flynn LL, Anderton RS, Mastaglia FL, Theunissen F, James I, et al. Disease-modifying effects of an SCAF4 structural variant in a predominantly SOD1 ALS cohort. Neurol Genet.&#xa0;2020;6:e470. 10.1212/NXG.0000000000000470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357414</ArticleId><ArticleId IdType="pubmed">32754644</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregersen LH, Mitter R, Ugalde AP, Nojima T, Proudfoot NJ, Agami R, et al. SCAF4 and SCAF8, mRNA anti-terminator proteins. Cell. 2019;177(7):1797&#x2013;813. e18. doi: 10.1016/j.cell.2019.04.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.04.038</ArticleId><ArticleId IdType="pmc">PMC6579486</ArticleId><ArticleId IdType="pubmed">31104839</ArticleId></ArticleIdList></Reference><Reference><Citation>Fliedner A, Kirchner P, Wiesener A, van de Beek I, Waisfisz Q, van Haelst M, Scott DA, Lalani SR, Rosenfeld JA, Azamian MS, Xia F, Dutra-Clarke M, Martinez-Agosto JA, Lee H, Noh GJ, Lippa N, Alkelai A, Aggarwal V, Agre KE, Gavrilova R, Mirzaa GM, Straussberg R, Cohen R, Horist B, Krishnamurthy V, McWalter K, Juusola J, Davis-Keppen L, Ohden L, van Slegtenhorst M, de Man SA, Ekici AB, Gregor A, van de Laar I, Zweier C, Nelson SF, Grody WW, Lee H, Deignan JL, Kang SH, Arboleda VA, Senaratne TN, Dorrani N, Dutra-Clarke MS, Kianmahd J, Hinkamp FL, Neustadt AM, Martinez-Agosto JA, Fogel BL, Quintero-Rivera F. Variants in SCAF4 cause a neurodevelopmental disorder and are associated with impaired mRNA processing. Am J Hum Genet. 2020;107(3):544&#x2013;554. doi: 10.1016/j.ajhg.2020.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2020.06.019</ArticleId><ArticleId IdType="pmc">PMC7477272</ArticleId><ArticleId IdType="pubmed">32730804</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ze M, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, San Juan IG, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Anderton RS, Mastaglia FL, Flynn LL, Winter SJ, James I, et al. Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Front Aging Neurosci. 2021;13:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8033025</ArticleId><ArticleId IdType="pubmed">33841129</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Humphrey J, Pickles S, Brown A-L, Hill SE, Kachergus J, Shi J, Heckman MG, Spiegel MR, Cook C, Song Y, Yue M, Daughrity LM, Carlomagno Y, Jansen-West K, de Castro CF, DeTure M, Koga S, Wang YC, Sivakumar P, Bodo C, Candalija A, Talbot K, Selvaraj BT, Burr K, Chandran S, Newcombe J, Lashley T, Hubbard I, Catalano D, Kim D, Propp N, Fennessey S, NYGC ALS Consortium. Fagegaltier D, Phatnani H, Secrier M, Fisher EM, Oskarsson B, van Blitterswijk M, Rademakers R, Graff-Radford NR, Boeve BF, Knopman DS, Petersen RC, Josephs KA, Thompson EA, Raj T, Ward M, Dickson DW, Gendron TF, Fratta P, Petrucelli L. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Investig. 2020;130(11):6080&#x2013;6092. doi: 10.1172/JCI139741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139741</ArticleId><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Zhang Y, Wang M, Song W-M, Shen Q, McKenzie A, Choi I, Zhou X, Pan PY, Yue Z, Zhang B. The landscape of multiscale transcriptomic networks and key regulators in Parkinson&#x2019;s disease. Nat Commun. 2019;10(1):1&#x2013;15. doi: 10.1038/s41467-019-13144-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13144-y</ArticleId><ArticleId IdType="pmc">PMC6868244</ArticleId><ArticleId IdType="pubmed">31748532</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Nikolakopoulos S, Roes KCB, Kendall L, Han SS, Lavrov A, et al. Challenging the established order: innovating clinical trials for amyotrophic lateral sclerosis. Neurology. 2021. 10.1212/WNL.0000000000012545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456357</ArticleId><ArticleId IdType="pubmed">34315786</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J. C9orf72 and the care of the patient with ALS or FTD: Progress and recommendations after 10 years. Neurol Genet. 2021;7(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862089</ArticleId><ArticleId IdType="pubmed">33575483</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856&#x2013;860. doi: 10.1038/ng.3314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3314</ArticleId><ArticleId IdType="pubmed">26121088</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotunno MS, Bosco DA. An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. Front Cell Neurosci. 2013;7:253. doi: 10.3389/fncel.2013.00253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00253</ArticleId><ArticleId IdType="pmc">PMC3863749</ArticleId><ArticleId IdType="pubmed">24379756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Homma K, Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv Biol Regul. 2016;60:95&#x2013;104. doi: 10.1016/j.jbior.2015.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2015.10.006</ArticleId><ArticleId IdType="pubmed">26563614</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Kordasiewicz HB, Cleveland DW. Antisense drugs make sense for neurological diseases. Ann Rev Pharmacol Toxicol. 2020;61:2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8682074</ArticleId><ArticleId IdType="pubmed">33035446</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?&#xa0;Front Aging Neurosci. 2017;9:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis&#x2014;past, present, and future. Med Res Rev. 2020;40(4):1352&#x2013;1384. doi: 10.1002/med.21661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21661</ArticleId><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>Vejux A, Namsi A, Nury T, Moreau T, Lizard G. Biomarkers of amyotrophic lateral sclerosis: current status and interest of oxysterols and phytosterols.&#xa0;Front Mol Neurosci. 2018;11:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5797798</ArticleId><ArticleId IdType="pubmed">29445325</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577&#x2013;589. doi: 10.1038/s41582-018-0058-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Agah E, Saleh F, Moghaddam HS, Saghazadeh A, Tafakhori A, Rezaei N. CSF and blood biomarkers in amyotrophic lateral sclerosis: protocol for a systematic review and meta-analysis. Syst Rev. 2018;7(1):237. doi: 10.1186/s13643-018-0913-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-018-0913-4</ArticleId><ArticleId IdType="pmc">PMC6300914</ArticleId><ArticleId IdType="pubmed">30572951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Saito T. A prognostic biomarker in amyotrophic lateral sclerosis. Clin Neurol. 2018;58(12):729&#x2013;736. doi: 10.5692/clinicalneurol.cn-001220.</Citation><ArticleIdList><ArticleId IdType="doi">10.5692/clinicalneurol.cn-001220</ArticleId><ArticleId IdType="pubmed">30487362</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>